In patients with acute myeloid leukemia (AML), the presence of residual disease at day 14 after primary induction therapy warrants consideration of a second induction cycle. However, data to guide retreatment decisions in such patients are presently limited. Here, we retrospectively reviewed data from 176 patients with AML treated at our institution with a second induction chemotherapy regimen because of day 14 residual disease. Clinical variables and nadir bone marrow features were assessed for correlations with complete remission (CR) and overall survival (OS). In our patient group, 59% achieved CR after a second induction course. Median OS for the entire group was 12.40 months (95% CI, 9.90-14.90) but 19.07 months (95% CI, 13.13-25.01) for those who attained a CR. Nadir marrow hypocellularity (P < 0.001) at day 14, absolute blast reduction of >50% (P 5 0.030), and de novo disease status (P 5 0.018) were significantly correlated with CR achievement after re-induction. Marrow hypocellularity at day 14 was the most significant predictor of CR on multivariate analysis (P < 0.001). Nadir marrow features did not independently correlate with OS when accounting for CR status. Re-induction was successful in achieving CR in most patients. Study patients who did not achieve CR were more likely to have nonhypocellular marrows.
| I N T R O D U C T I O N
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with 18 000 new cases and 10 000 deaths attributable to this disease every year. 1 At the time of an initial AML diagnosis, multiple patient-specific and disease-specific features may predict for patient outcomes. For example, advanced age and poor functional status correlate with reduced overall survival, in part related to increased treatment-related toxicity. 2 The presence of antecedent hematologic disorders and high-risk cytogenetic abnormalities predict for both poor treatment response and shorter survival, attributed to increased chemotherapy resistance and more aggressive disease biologies. [3] [4] [5] Standard induction chemotherapy for fit adults with AML in the United States utilizes a single cycle of a cytarabine-based and anthracycline-based regimen. After the completion of initial induction therapy, the day 14 bone marrow biopsy provides the first dynamic assessment of disease response. Previously published analyses of nadir marrow features have demonstrated that excess blasts at this time point correlate with a failure to achieve a complete remission (CR) in the absence of further therapy. 6, 7 Based on these data, current guidelines recommend administering a second induction course if the day 14 bone marrow contains more than 5% to 10% blasts. 8 A large retrospective analysis of several randomized controlled trials suggested that patients who achieve a CR after a second induction course have overall survival rates similar to those shown in patients who only require a single induction. 9 Despite this, many patients will not achieve a CR after a second induction, and the outcomes for such patients appear to be extremely poor.
Addressing the refractory population as a whole, there is a paucity of data to help predict which patients are likely to achieve a CR with further therapy. Such information could potentially help guide retreatment decisions. Furthermore, it is unknown whether the initial day 14 marrow features maintain prognostic significance in those who go on to receive a second induction course.
In an effort to better elucidate outcomes and decision making during re-induction for residual disease at day 14, we retrospectively reviewed outcomes of patients with AML who required doubleinduction chemotherapy at our institution. 
| MATERIALS A ND METHODS

| Study endpoints
The primary endpoints of our analyses were CR or complete remission with low platelets (CRi) and overall survival (OS) rate. Response to treatment was defined per the International Working Group criteria. 11 OS was defined for all patients as the time from date of AML diagnosis to date of death. If no death, OS was censored at the time of last follow-up.
| Statistical analyses
Patient characteristics were summarized using medians and ranges for continuous variables and frequency and percentages for discrete varia- 
| R E S U L T S
We identified 176 patients with AML who received a second induction for the presence of residual disease at day 14 following primary induction chemotherapy. The baseline characteristics of the group are summarized in Table 1 A reduction in the absolute blast count of greater than 50% at day 14 was associated with the achievement of CR/CRi in 68.4% versus 48.6% of those with a day 14 absolute blast count reduction of less than 50% (P 5 0.03).
Features that did not demonstrate a significant correlation with CR/CRi included patient age (P 5 0.680), cytogenetic risk (P 5 0.060), the use of a high-dose cytarabine-containing chemotherapy regimen (P 5 0.806), and the length of re-treatment delay (P 5 0.102). Of those patients with an absolute blast reduction less than 50% at day 14, 78.4% went on to receive a high-dose cytarabinecontaining regimen versus 59.1% of patients with absolute blast count reductions greater than 50% (P 5 0.001). We were not able to formally evaluate the prognostic impact of histological subgroups or bone marrow fibrosis, since this information was not consistently available in the bone marrow reports. On multivariate analyses of CR ( for those with antecedent hematologic disorders (P < 0.001) ( Figure   1B those who did not achieve CR (P < 0.001). On multivariate analysis of OS (Table 3) , age <60 years, marrow hypocellularity of < 20% at day 14, and cytogenetic risk all retained statistical significance. However, the nadir marrow cellularity did not maintain significance independent of final CR status (P 5 0.168).
| DISCUSSION
In the present study, 59% of patients who received a second induction for excess blasts at day 14 went on to achieve CR/CRi, indicating a reasonably good rate of remission in patients with presumed gross residual disease at the time of nadir following first induction. The CR rate and median OS in this analysis compare favorably to published outcomes from prospective trials, as well as our own previously reported institutional experience. [12] [13] [14] [15] The strongest predictor of CR in this analysis was the day 14 bone marrow cellularity after first induction.
To our knowledge, the correlation between original nadir marrow cellularity and response to a second induction has not been previously
described. An absolute blast count reduction greater than 50% after first induction also appeared to predict for CR after a second cycle, second cycle with a lower tumor burden. Although nadir marrow blast counts are typically used to guide re-treatment decisions, it has long been recognized that some patients with excess blasts at day 14 may go on to achieve a CR even without further therapy. [16] [17] [18] [19] It has been proposed that perhaps populations of immature cells interpreted as residual AML may actually represent normal regeneration. More definitive analysis of residual leukemic clones by newer technologies (e.g., high-sensitivity sequencing) may serve to better address this issue, and this approach already appears promising for demonstrating prognostic significance in the remission setting. 20 In our study, the relative lack of ambiguity in the estimation of marrow cellularity at day 14 may explain why it is a more accurate predictive marker in this setting. However, it is important to keep in mind also that the poor prognostic nadir marrow features identified here would be unlikely to serve as the sole deciding factors on whether to administer a second induction cycle, since these poor prognosis patients still had a >40% chance of achieving CR with a second induction.
Prospective data on predictive markers in double induction therapy are mostly from European trials wherein the second induction cycle is preplanned. For example, the AMLCG 1992 trial treated 449 newly diagnosed patients with a cycle of standard-dose cytarabine plus daunorubicin and thioguanine followed by randomization to either a second cycle of the same regimen or a cycle of high-dose cytarabine with mitoxantrone. The authors reported lower CR rates and OS in those patients with increased blasts at day 16 after initial induction. 21 Furthermore, patients with excess blasts who received blasts at day 14, overall survival and relapse rates were inferior, even in those patients who achieved CR after the second induction regimen. As noted, the approach to treatment in those trials was different from that explored in the present analysis, in that the second induction regimen in those trials was given in a predetermined fashion, regardless of nadir marrow status. This is an intensification strategy that is not common practice in the United States, where a second induction is traditionally administered only in the presence of residual disease. In a more relevant analysis of six separate ECOG trials, during which patients only received a second induction if the nadir bone marrow demonstrated more than 5% blasts, overall survival was the same for those patients who achieved CR, regardless of whether they required one or two induction regimens to achieve that response. 9 Although this analysis provides important prognostic information, it does not provide predictive response data for the residual disease population as a whole.
This study is, of course, limited by its retrospective nature. At the time of treatment, decisions regarding whether to initiate a second induction and the choice of specific regimens were based on individual physician discretion. At present, the decision to administer additional chemotherapy in the presence of residual disease at day 14 remains mostly empiric, with little prospective evidence to guide decision making. Furthermore, it is unlikely that a randomized trial will ever be conducted to answer this question. In this regard, our study is unique in that it attempts to analyze the impact of dynamic marrow features on outcomes in patients who go on to receive second induction and provides data from a time point that could potentially impact treatment decisions.
In conclusion, double induction chemotherapy for presumed residual AML at day 14 (following initial induction) was successful in achieving CR in the majority of patients. However, a substantial minority did not achieve CR after two cycles of therapy, particularly patients with nonhypocellular marrows at day 14. Determination of predictive factors for failure to achieve a CR after a second induction could potentially spare patients further chemotherapy-related toxicity while also identifying such patients for whom investigational approaches may be more appropriate.
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